Get the Stockscreener App
932.06
2.35%
21.37
After Hours:
930.01
-2.05
-0.22%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $932.06, with a volume of 2.24M.
It is up +2.35% in the last 24 hours and up +1.21% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
See More
Previous Close:
$910.69
Open:
$916.04
24h Volume:
2.24M
Relative Volume:
0.75
Market Cap:
$885.83B
Revenue:
$38.92B
Net Income/Loss:
$7.34B
P/E Ratio:
171.99
EPS:
5.4193
Net Cash Flow:
$-3.63B
1W Performance:
+5.06%
1M Performance:
+1.21%
6M Performance:
+22.71%
1Y Performance:
+53.99%
1-Day Range:
$911.18
$932.24
1-Week Range:
$889.57
$932.24
52-Week Range:
$547.61
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock - The Motley Fool
Eli Lilly and Company (LLY): Among the Most Promising Growth Stocks According to Hedge Funds - Insider Monkey
FDA to review decison to end of Zepbound shortage (NYSE:LLY) - Seeking Alpha
The Ultimate Biotech Stock to Buy With $100 Right Now - The Motley Fool
US FDA to reconsider decision barring compounded versions of Lilly weight loss drug - Reuters.com
Why Lilly is pouring billions into LEAP - Indianapolis Business Journal
Eli Lilly Expects Zepbound Approval in Japan by Mid-2025, Eyes Weight-Loss Market - Yahoo Finance
Eli Lilly obesity drug on track for Japan approval next year: CEO - Nikkei Asia
Lilly goes all-in on AI with new exec position—Chutes & Ladders - Fierce Biotech
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.
Lilly threatens copycat drugmakers after Zepbound shortage - MedWatch
As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle - STAT
KeyBioscience and Eli Lilly extend partnership for obesity treatments - Pharmaceutical Technology
Warning: This Skyrocketing Stock Has a Hidden Risk - The Motley Fool
Nordic Bioscience lands billion-dollar deal with Eli Lilly - MedWatch
Novo and Lilly contender Zealand Pharma heralds its obesity drug alternative: It's our 'crown jewel' - CNBC
Eli Lilly Tells Mich. Justices It's 'Wrong Time' For Insulin Case - Law360
Holcomb appoints Lilly CEO to Purdue board - Inside INdiana Business
Don't Sleep on Skye Bioscience—This Weight Loss Drug Could Soar - Benzinga
Michigan AG Seeks State Justices' Aid in Eli Lilly Insulin Probe - Bloomberg Law
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves - AOL
Global Antiemetics Drugs Market to Exhibit Growth at a CAGR of ~6% by 2030 | DelveInsight - GlobeNewswire Inc.
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves - Benzinga
Eli Lilly has an AI chief, telehealth’s DEA troubles, and FDA’s thinking on AI in clinical trials - STAT
Lilly and insitro team up to develop AI-powered siRNA metabolic drugs - Pharmaceutical Technology
Lilly threatens legal action against copycat Zepbound providers: report (NYSE:LLY) - Seeking Alpha
Lilly Fires Warning Shot at Copycat Drug Makers After Shortage - Bloomberg
Truist highlights ongoing investments in manufacturing as a driver for Eli Lilly shares By Investing.com - Investing.com UK
Lilly and insitro partner to develop novel drugs for metabolic diseases - World Pharmaceutical Frontiers
Eli Lilly hires first chief AI officer - MedWatch
2 No-Brainer Dividend Growth Stocks to Buy Right Now - The Motley Fool
The Crackdown on Compounded GLP-1 Meds Has Begun - WIRED
Eli Lilly 2024: The “it” drug - PharmaLive
Eli Lilly & Co. stock rises Wednesday, still underperforms market - MarketWatch
On Nobel day for AI in drug discovery, Peninsula biotech, big drugmaker strike AI dealSan Francisco Business Times - The Business Journals
Lilly, Insitro Ink Unique AI Deal, Eye Novel Treatments for Metabolic Diseases - BioSpace
Lilly weight-loss drug copycat makers sue FDA for taking drugs off shortage list - Indiana Lawyer
Prime Medicine lays off workers as it trims pipeline - STAT
insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases - Yahoo Finance
Germany Pharmaceuticals Market Report 2024-2028: Consolidation through Mergers and Acquisitions Catalyzing Growth - GlobeNewswire Inc.
Here's Why Everybody's Talking About Scholar Rock Right Now - The Motley Fool
Eli Lilly and Company (LLY): Stock That Will Make You Rich in 5-10 Years - Insider Monkey
Eli Lilly and Company (LLY): Stock That Will Make You Rich in 5-10 Years - Yahoo Finance
Lilly’s Sprawling Obesity Clinical Program Underscores Challenges for Biotechs - BioSpace
Why Eli Lilly Was Such a Healthy Stock Today - The Motley Fool
Working Together To Advance Health Equity - Essence
Lilly weight-loss drug copycat makers sue FDA for taking drugs off shortage list - Indianapolis Business Journal
Stock Quote & Chart - Investors | Eli Lilly and Company
Qinotto and Lilly Enter Research Collaboration and License Agreement - GlobeNewswire Inc.
Eli Lilly obesity drug shortage ends fueling lawsuit against FDA - MSN
Lilly appoints Thomas J. Fuchs as the company’s first chief AI officer - Investors | Eli Lilly and Company
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lilly Eli Co Stock (LLY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | 10% Owner |
Sep 03 '24 |
Sale |
966.69 |
24,084 |
23,281,840 |
96,891,978 |
| LILLY ENDOWMENT INC | 10% Owner |
Aug 27 '24 |
Sale |
968.46 |
24,552 |
23,777,668 |
96,916,062 |
0.59%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):